Aclaris Therapeutics, Inc.

Listed Company

ACRSCIK 0001557746NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$7.83M

Net Income

$-64.92M

Total Assets

$160.46M

Equity

$103.08M

Shares Out

139.66M

Op. Cash Flow

$-47.11M

ACRS$5.67+256.60% · past yearDBEQ Basic

Daily closing prices

Business

Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing novel small-molecule kinase inhibitors and monoclonal antibodies for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. Key programs include bosakitug (anti-TSLP monoclonal antibody), ATI-2138 (ITK/JAK3 dual inhibitor), and ATI-052 (anti-TSLP/anti-IL-4Ra bispecific), targeting atopic dermatitis and asthma. The company pursues an out-licensing model, partnering with third parties for development, regulatory approval, and commercialization while relying on contract manufacturers for production.

Summary from 10-K filed 2026-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	8	19	31	30	7
Cost of revenue	2	3	3	4	5
Research and development	53	34	98	78	44
General and administrative	22	22	32	25	24
Licensing	5	13	15	8	—
Revaluation of contingent consideration	2	3	−27	5	24
In-process research and development	—	87	7	—	—
Total costs and expenses	84	161	129	120	96
Loss from operations	−76	−142	−97	−90	−90
Interest income	8	8	9	—	—
Non-cash royalty income	4	2	—	—	—
Total other income	11	10	9	—	—
Net loss	−65	−132	−88	−87	−91
Net loss per share, basic	−0.53	−1.71	−1.27	−1.33	−1.6
Net loss per share, diluted	−0.53	−1.71	−1.27	−1.33	−1.6
Weighted average common shares outstanding, basic	123	77	70	65	57
Weighted average common shares outstanding, diluted	123	77	70	65	57
Unrealized gain on marketable securities, net of tax of $0	513,000	203,000	791,000	−673,000	−229,000
Total other comprehensive income	513,000	203,000	791,000	−673,000	−130,000
Comprehensive loss	−64	−132	−88	−88	−91

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	20	25	40	45	27
Short-term marketable securities	71	89	79	172	164
Accounts receivable, prepaid expenses and other current assets	6	12	—	—	—
Total current assets	96	126	129	232	205
Marketable securities	61	90	63	12	34
Property and equipment, net	761,000	1	2	1	1
Other assets	3	3	4	3	4
Total assets	160	220	197	255	251
Accounts payable	13	5	9	10	10
Accrued expenses	9	20	19	9	10
Deferred income	4	4	—	—	—
Other current liabilities	3	3	3	—	693,000
Total current liabilities	29	32	31	22	23
Other liabilities	2	4	3	2	2
Deferred income, net of current portion	16	20	—	—	—
Contingent consideration	11	9	6	33	28
Total liabilities	57	65	40	57	54
Preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued or outstanding at December 31, 2025 and December 31, 2024	—	—	—	—	—
Common stock, $0.00001 par value; 400,000,000 and 200,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; 120,499,433 and 107,850,124 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	1,000	1,000	1,000	1,000	1,000
Additional paidin capital	1,070	1,058	928	881	793
Accumulated other comprehensive income	610,000	97,000	−106,000	−897,000	−224,000
Accumulated deficit	−968	−903	−771	−682	−595
Total stockholders' equity	103	156	157	198	197
Total liabilities and stockholders' equity	160	220	197	255	251

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−65	−132	−88	−87	−91
Depreciation and amortization	454,000	807,000	863,000	797,000	923,000
Stock-based compensation expense	12	11	21	15	14
Accounts receivable, prepaid expenses and other assets	6	−5	—	—	—
Accounts payable	8	−4	−1	368,000	4
Accrued expenses and other liabilities	−8	−4	12	—	—
Deferred income	−4	24	—	—	—
Net cash used in operating activities	−47	−20	−78	−68	−52
Purchases of property and equipment	−111,000	−121,000	−1	−605,000	−308,000
Purchases of marketable securities	−40	−120	−136	−165	−235
Proceeds from sales and maturities of marketable securities	89	86	183	178	68
Payments of deferred transaction consideration for in-licensed assets	−833,000	—	—	—	—
Acquisition of in-licensed assets, including transaction costs	—	−36	—	—	—
Net cash provided by (used in) investing activities	48	−70	46	13	−168
Proceeds from issuance of common stock under securities purchase agreement, net of issuance costs	—	75	27	73	—
Payments of deferred transaction consideration for in-licensed assets	−5	—	—	—	—
Payments of employee withholding taxes related to restricted stock unit award vesting	−446,000	−409,000	−102,000	−34,000	−3
Proceeds from exercise of employee stock options and the issuance of stock	—	32,000	94,000	157,000	1
Net cash (used in) provided by financing activities	−6	75	27	73	225
Net decrease in cash and cash equivalents	−5	−15	−5	18	5
Additions to property and equipment included in accounts payable	21,000	—	—	24,000	143,000
Fair value of warrants issued in connection with in-license agreement	—	45	—	—	—
Deferred transaction consideration in connection with in-license agreement	—	6	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Aclaris Therapeutics, Inc.'s CIK number?

Aclaris Therapeutics, Inc.'s SEC CIK number is 0001557746 (1557746). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Aclaris Therapeutics, Inc.'s SEC filings?

All of Aclaris Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Aclaris Therapeutics, Inc. last report earnings?

Aclaris Therapeutics, Inc. (ACRS) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-056669). This is Aclaris Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Aclaris Therapeutics, Inc.'s most recent earnings 8-K?

Aclaris Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001104659-26-056669. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Aclaris Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →